ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1577

Analysis of Takayasu’s Arteritis as Risk Factor for Acute Coronary Syndrome
Abstract Number: 0202

Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)
Abstract Number: 0500

Analysis of the Probability of Retention of Golimumab as a Two-phase Exponential Decay Curve in Rheumatoid Arthritis or Spondyloarthropathies to Identify Patients with Higher Probability of Long-term Retention
Abstract Number: 0158

Analyzing User Log Data to Track Provider Use of an EHR-based Dashboard for Rheumatoid Arthritis Outcomes
Abstract Number: 2381

ANCA-associated Vasculitis and Renal Disease in a Multidisciplinary Outpatient Clinic in Northern Spain
Abstract Number: 1534

ANCA-associated Vasculitis Incidence in a Norther Spanish Health Region
Abstract Number: 1715

Androgen Treatment Exhibits a Protective Role Against Focal Erosions in TNF-Induced Inflammatory Arthritis in Mice
Abstract Number: 2477

Anifrolumab Normalizes the Type I Interferon Signature in a Cohort of Patients with Type I Interferonopathies
Abstract Number: 0333

Ankylosing Spondylitis Patient Perspective on Living with Flares and Impact on Quality of Life
Abstract Number: 0166

Annual Economic Burden for Patients with Familial Hypophosphatemia in the United States
Abstract Number: 0277

Anti-carbamylated Antibodies in Autoimmunity – Focus on Their Diagnostic and Prognostic Value: A Systematic Review and Meta-analysis
Abstract Number: 0050

Anti-Citrullinated Histone Antibody CIT-013, a Dual Action Therapeutic for Neutrophil Extracellular Trap Associated Autoimmune Disease
Abstract Number: 2193

Anti-citrullinated Protein Antibodies in Sjögren’s Syndrome Define a Subset of Patients with Lower B Cell Activation Markers and Higher Risk of Lung Involvement
Abstract Number: 1077

Anti-drug Antibodies Formation During Tapering and Stopping of Methotrexate in Rheumatoid Arthritis Patients with Longstanding Use of Adalimumab
Abstract Number: 0934

Anti-fibrotic Effects of MT-5562, a Novel Potent Selective Autotaxin Inhibitor, in Preclinical Studies: Roles of Lysophosphatidic Acid in Autoimmune Diseases and Clues to Treat Skin and Lung Fibrosis in Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].